Premium
Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer
Author(s) -
Arbour Kathryn C.,
Riely Gregory J.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31289
Subject(s) - epidermal growth factor receptor , lung cancer , medicine , mutant , cancer research , epidermal growth factor , cancer , targeted therapy , oncology , receptor , biology , genetics , gene
Progress in the rational development of therapy for patients with epidermal growth factor receptor‐mutant lung cancer depends on pursuing multiple parallel approaches to the problem of resistance. New treatment strategies evaluating not only new drugs, but also novel dosing strategies and novel combinations based on off‐target mechanisms of resistance and general principles of tumor biology, have great potential to improve treatments for patients with epidermal growth factor receptor‐mutant lung cancer. See also pages 2355‐64, this issue.